Cited by 5,504Antiplatelet Therapy and Cardiovascular DiseasesLipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

Open access
Ridker, Paul M., Cushman, Mary, Stampfer, Meir J., Tracy, Russell P., Hennekens, Charles H.·1997·New England Journal of Medicine

Abstract

BACKGROUND: Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin decreases the risk. METHODS: We measured plasma C-reactive protein, a marker for systemic inflammation, in 543 apparently healthy men participating in the Physicians' Health Study in whom myocardial infarction, stroke, or venous thrombosis subsequently developed, and in 543 study participants who did not report vascular disease during a follow-up period exceeding eight years. Subjects were randomly assigned to receive aspirin or placebo at the beginning of the trial. RESULTS: Base-line plasma C-reactive protein concentrations were higher among men who went on to have myocardial infarction (1.51 vs. 1.13 mg per liter, P<0.001) or ischemic stroke (1.38 vs. 1.13 mg per liter, P=0.02), but not venous thrombosis (1.26 vs. 1.13 mg per liter, P=0.34), than among men without vascular events. The men in the quartile with the highest levels of C-reactive protein values had three times the risk of myocardial infarction (relative risk, 2.9; P<0.001) and two times the risk of ischemic stroke (relative risk, 1.9; P=0.02) of the men in the lowest quartile. Risks were stable over long periods, were not modified by smoking, and were independent of other lipid-related and non-lipid-related risk factors. The use of aspirin was associated with significant reductions in the risk of myocardial infarction (55.7 percent reduction, P=0.02) among men in the highest quartile but with only small, nonsignificant reductions among those in the lowest quartile (13.9 percent, P=0.77). CONCLUSIONS: The base-line plasma concentration of C-reactive protein predicts the risk of future myocardial infarction and stroke. Moreover, the reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199704033361401

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy adults: implications for reference interval and epidemiologic methods. Clin Chem 1997;43:52-8.
  2. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism. Circulation (in press).

Cited by

Sorted by citations

Authors
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Vermont (US)
Venue
New England Journal of Medicine
Published
1997-04-03
Volume
336
Issue
14
Pages
973-979
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2316376271
Cited by
5,504
References
36
Citations by year
2026: 67 · 2025: 81 · 2024: 77 · 2023: 92 · 2022: 95 · 2021: 103 · 2020: 100 · 2019: 115 · 2018: 107 · 2017: 98 · 2016: 114 · 2015: 135 · 2014: 141 · 2013: 171 · 2012: 164
FWCI
148.83
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association
  • National Institutes of Health (CA 34944, CA 40360, HL-26490)
  • National Heart, Lung, and Blood Institute (HL-34595, R01HL046690, HL 26490, HL-46690, R01HL034595)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
C-reactive protein, inflammation, aspirin, cardiovascular disease, myocardial infarction, ischemic stroke, venous thrombosis, atherothrombosis, anti-inflammatory therapy, cardiovascular risk prediction, Physicians' Health Study
MeSH terms
Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, C-Reactive Protein, Brain Ischemia, Humans, Inflammation, Male, Middle Aged, Myocardial Infarction, Risk, Thrombophlebitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review